Ponatinib versus Allogeneic Stem Cell Transplant for Patients with CML or Ph+ ALL with the T315I Mutation
Nicolini FE et al. The impact of ponatinib versus allogeneic stem cell transplant (SCT) on outcomes in patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with the T315I mutation. Proc ASH 2015;Abstract 480.
Dr Stone is Director of the Adult Leukemia Program at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School in Boston, Massachusetts.
|